Enables Site-Specific Detection and Inhibition of Disease-Associated Tau Protein
This aptamer-based molecular recognition platform enables site-specific detection and inhibition of pathological tau protein in neurodegenerative disorders. Tau is a microtubule-associated protein enriched in neuronal axons within the central nervous system. Under normal physiological conditions, tau promotes the assembly and stabilization of microtubules, maintaining neuronal structure and intracellular transport. In several neurodegenerative conditions, tau becomes abnormally phosphorylated, causing it to dissociate from microtubules and aggregate within neurons, disrupting neuronal stability and contributing to neuronal death. Tau pathology is a defining feature of several neurological disorders, including Alzheimer's disease and chronic traumatic encephalopathy (CTE). In the United States, roughly 1.9 million new traumatic brain injury (TBI) cases occur annually, many triggering chronic tau aggregation and accelerate neurodegeneration. The global TBI-diagnostic market was valued at approximately $1.06 billion in 2024 and is projected to exceed $2.5 billion by 2031, reflecting growing demand for rapid and accurate neurological biomarker detection. Existing detecting platforms are costly and require large sample volumes, creating a clear opportunity for a low-cost, high-sensitivity aptamer solution.
Researchers at the University of Florida developed an aptamer platform for enabling the selective recognition of tau and its phosphorylated forms using short, structured DNA sequences engineered for high binding specificity. Aptamers offer several advantages over conventional antibodies, including smaller size, chemical stability, and the ability to be synthetically produced and modified. These properties make them versatile molecular tools for biomarker detection, imaging, and therapeutic targeting, positioning the tau-binding aptamer technology as a promising platform for developing next-generation diagnostics and treatments for tau-related neurological disorders.
Application
This aptamer-based molecular recognition platform can be used in the development of diagnostic assays and therapeutic strategies for detecting and targeting tau pathology associated with neurodegenerative diseases and traumatic brain injury
Advantages
- Enables precise recognition of hyperphosphorylated tau variants, increasing diagnostic sensitivity to differentiate between healthy and pathological protein forms
- Combines high-fidelity detection with potent inhibition, accelerating early disease detection and halting tau aggregation
- Crosses the blood-brain barrier efficiently, delivering diagnostic or therapeutic molecules directly into the brain
- Offers smaller sizes than antibodies, improving tissue diffusion
- Reduces production cost, allowing chemical synthesis at scale
Technology
The platform uses high-affinity DNA aptamers to specifically target and bind to the tau protein at critical phosphoryl table sites, providing a versatile avenue for the detection and treatment of tauopathy-related neurodegenerative disorders. By enabling the precise recognition of pathological tau forms, the system facilitates early-stage diagnosis and real-time monitoring of disease progression. The platform is compatible with multiple biological matrices, including cerebrospinal fluid and blood, and supports diverse applications such as enzyme-linked aptamer-based assays (ELASA), molecular beacon-based sensing, and targeted therapeutic inhibition of tau aggregation. Designed for clinicians and researchers, this platform improves diagnostic sensitivity, enables the rapid evaluation of neurotoxic protein levels, and provides a programmable, non-immunogenic tool for arresting the progression of conditions like Alzheimer’s disease and CTE without the limitations of traditional antibody-based methods.
Brochure
